ALCHEMAB INC

From the company

Alchemab Therapeutics has developed a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires. Using well-defined patient samples, deep B cell sequencing, and computational analysis, it identifies convergent protective antibody responses among individuals resilient to specific diseases. It is building a pipeline of protective therapeutics for hard-to-treat diseases, initially focused on neurodegenerative conditions and oncology.